Literature DB >> 15164094

Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1.

E Yagüe1, C F Higgins, S Raguz.   

Abstract

Overexpression of P-glycoprotein, encoded by the MDR1 gene, confers multidrug resistance (MDR) on cancer cells and is a frequent impediment to successful chemotherapy. Recent developments in the use of small interfering RNAs to inhibit specific protein expression have highlighted their potential use as therapeutic agents. We have expressed two different short hairpin RNAs from stably integrated plasmids in doxorubicin-resistant K562 leukaemic cells. The MDR1-targeted RNA interference (RNAi) resulted in decreased MDR1 mRNA, abolished P-glycoprotein expression, and completely reversed the MDR phenotype to that of the drug-sensitive K562 parental line. This study demonstrates that MDR, which is solely due to overexpression of P-glycoprotein, can be reversed by RNAi. These target sequences can in the future be integrated into gene therapy vectors with potential clinical application.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15164094     DOI: 10.1038/sj.gt.3302269

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  14 in total

1.  siRNA-mediated down-regulation of P-glycoprotein in a Xenograft tumor model in NOD-SCID mice.

Authors:  Meysam Abbasi; Hamidreza Montazeri Aliabadi; Elaine H Moase; Afsaneh Lavasanifar; Kamaljit Kaur; Raymond Lai; Charles Doillon; Hasan Uludağ
Journal:  Pharm Res       Date:  2011-06-03       Impact factor: 4.200

2.  Reversal of adriamycin resistance in human mammary cancer cells by small interfering RNA of MDR1 and MDR3 genes.

Authors:  Lan Xiao; Rui Gao; Shi Lu; Lirong Ren; Zehua Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

3.  Reversing multidrug resistance by RNA interference through the suppression of MDR1 gene in human hepatoma cells.

Authors:  Xiao-Ping Chen; Qi Wang; Jian Guan; Zhi-Yong Huang; Wan-Guang Zhang; Bi-Xiang Zhang
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

Review 4.  Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles.

Authors:  Chiranjeevi Peetla; Sivakumar Vijayaraghavalu; Vinod Labhasetwar
Journal:  Adv Drug Deliv Rev       Date:  2013-09-19       Impact factor: 15.470

Review 5.  Personalized cancer approach: using RNA interference technology.

Authors:  John Nemunaitis; Donald D Rao; Shi-He Liu; F Charles Brunicardi
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

6.  Role of the highly structured 5'-end region of MDR1 mRNA in P-glycoprotein expression.

Authors:  Rebecca A Randle; Selina Raguz; Christopher F Higgins; Ernesto Yagüe
Journal:  Biochem J       Date:  2007-09-15       Impact factor: 3.857

7.  The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance.

Authors:  Yogesh B Patil; Suresh K Swaminathan; Tanmoy Sadhukha; Linan Ma; Jayanth Panyam
Journal:  Biomaterials       Date:  2009-10-01       Impact factor: 12.479

8.  Reversal of multi-drug resistance by pSUPER-shRNA-mdr1 in vivo and in vitro.

Authors:  Guang-Dong Pan; Jian-Qing Yang; Lv-Nan Yan; Guang-Ping Chu; Qiang Liu; Yi Xiao; Lin Yuan
Journal:  World J Gastroenterol       Date:  2009-01-28       Impact factor: 5.742

9.  Combination of siRNA-directed Gene Silencing With Cisplatin Reverses Drug Resistance in Human Non-small Cell Lung Cancer.

Authors:  Shanthi Ganesh; Arun K Iyer; Jan Weiler; David V Morrissey; Mansoor M Amiji
Journal:  Mol Ther Nucleic Acids       Date:  2013-07-30       Impact factor: 10.183

10.  Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression.

Authors:  Kazuhisa Sugiu; Hiroshi Tazawa; Joe Hasei; Yasuaki Yamakawa; Toshinori Omori; Tadashi Komatsubara; Yusuke Mochizuki; Hiroya Kondo; Shuhei Osaki; Tomohiro Fujiwara; Aki Yoshida; Toshiyuki Kunisada; Koji Ueda; Yasuo Urata; Shunsuke Kagawa; Toshifumi Ozaki; Toshiyoshi Fujiwara
Journal:  Cancer Chemother Pharmacol       Date:  2021-06-10       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.